Introduction
In early January 2026, the biotechnology and pharmaceutical sectors face a major shift due to upcoming patent expirations and ongoing innovation. Reports from late 2025 highlight a significant patent cliff starting this year, with blockbuster drugs losing exclusivity and risking up to $236 billion in global sales by 2030. Key expirations include anticoagulants like Eliquis and diabetes treatments like Januvia, prompting companies to seek new protections. At the same time, patent filings rise in areas like AI-assisted drug discovery and advanced biologics. The USPTO and EPO report steady growth in biotech applications, driven by personalized medicine and gene therapies. Ongoing CRISPR disputes, including a May 2025 U.S. appeals court decision reviving priority claims for eukaryotic editing, add uncertainty to gene-related patents. mRNA platforms expand beyond COVID-19, with companies filing for broader applications in cancer and infectious diseases. These trends set the stage for 2026, as firms balance defending existing portfolios against generics while patenting breakthroughs in treatments and genetic work.
A patent in this field is a government-granted right that excludes others from making, using, or selling a new drug, biologic, or genetic invention for a limited period, often 20 years from filing, with extensions possible for regulatory delays.
Main Predictions for 2026
In 2026, patent strategies will focus on extending protections for existing drugs and securing new ones for emerging therapies. Companies will file more secondary patents—covering formulations, combinations, or methods of use—to delay generic entry amid the patent cliff. For instance, evergreening tactics around drugs like Eliquis may extend exclusivity into late 2020s through new claims.
Filings for gene-editing inventions will increase, building on CRISPR resolutions. As disputes clarify priority, winners will broaden portfolios for therapeutic applications, such as in sickle cell or rare diseases. Expect growth in patents for base editing or prime editing variants.
AI integration in discovery will drive specialized filings. Companies will patent AI-optimized molecules or screening methods, with human contributions emphasized to meet inventorship rules. Partnerships like those with tech firms will yield joint applications for predictive models in target identification.
Biologics and biosimilars will see targeted protections. Originators will patent manufacturing improvements or new indications, while biosimilar developers file for non-infringing processes. mRNA patents will expand for multi-valent vaccines or oncology uses, with lipid nanoparticle variations prominent.
Personalized medicine filings will rise, covering companion diagnostics or gene-specific therapies. Oncology and rare diseases will lead, supported by orphan drug incentives.
International approaches will use Patent Cooperation Treaty filings for key markets, with China and the U.S. seeing high activity. Overall, biotech patent applications could grow 5-10%, offsetting cliff impacts through pipeline protections.
Monetization via licensing will increase, especially for platform technologies like mRNA or gene delivery.
Challenges and Risks
Patenting drugs and genetic work in 2026 involves notable difficulties. The patent cliff threatens revenue, with generics and biosimilars eroding sales quickly for small molecules and gradually for biologics. Weak secondary patents face invalidation challenges.
Gene patents remain contentious. CRISPR disputes create uncertainty, delaying investments until priority settles. Strict sufficiency requirements at the EPO demand broad enabling disclosure, risking narrow or revoked claims.
AI-assisted inventions face inventorship hurdles. Proving significant human contribution is essential; overly reliant outputs may lack eligibility, pushing reliance on trade secrets.
High costs burden smaller entities. Prosecution, especially international, plus litigation for defenses, can exceed millions. Biosimilar pathways complicate entry without clear non-infringement.
Regulatory-patent linkage varies globally, with weaker enforcement in some markets allowing early generics. Evergreening criticism may spur reforms limiting secondary patents.
Data requirements for predictability grow. For gene therapies, showing efficacy across variants is tough, leading to objections.
These issues could slow innovation if protection seems unreliable or overly costly.
Opportunities
Despite risks, 2026 offers promising avenues for patenting medical and genetic advances. The cliff motivates robust pipelines, with patents on next-generation therapies providing new exclusivity.
Clearer CRISPR outcomes enable licensing, accelerating treatments for genetic disorders. Strong portfolios attract partnerships and funding.
AI tools speed discovery, allowing more filings for novel compounds. Documented human oversight ensures eligibility, rewarding efficient R&D.
Biosimilar competition drives originator innovation in improved versions, patentable for better delivery or efficacy.
Extensions like Patent Term Extensions compensate delays, extending high-value drug protection.
Global growth, especially in Asia, opens harmonized filings for broader coverage.
Orphan designations offer extra incentives for rare disease gene therapies.
Robust patents support high valuations, enabling M&A to fill gaps.
These factors encourage investment, ensuring rewards for breakthroughs while fostering competition post-expiry.
Conclusion
In 2026, patents on drugs and genes will navigate the patent cliff through defensive extensions and offensive filings in AI, gene editing, and biologics, though costs and uncertainties persist. Companies emphasizing human contributions, technical details, and strategic jurisdictions will secure stronger positions. The system promotes innovation and patient access via timed exclusivity, but adaptations address new tech and equity. Ahead, trends like multimodal AI and advanced editing suggest patents will remain vital for advancing treatments.
Comments are closed.
